Jazz Pharmaceuticals Plc Ireland: (NASD: JAZZ)

$61.34

1.34 (2.23%)

Volume 2,042,343

May 22 03:24 PM ET

Zacks Rank: 1-Strong Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		60.30 - 64.45
	
		52wk Low - High
		40.38 - 64.45
	
		Previous Close
		60.00
	
		Avg. Volume
		889,442
	
		Industry
		MED-DRUGS
	
		Market Cap
		3.48 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		2.07
	
		PE (Forward)
		10.77
	
		Current Year Est.
		5.57
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		1
Strong Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		108 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            10.77
                        
                            PEG Ratio
                            0.49
                        
                            Current Year Est.
                            5.57
                        
                            Current Quarter Estimate
                            1.37
                        
                            Most Accurate Estimate
                            1.37
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            4.83
                        
                            Expected Earnings Growth
                            22.13%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.   
Full JAZZ Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
JAZZ Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.37	1.44	5.57	6.98
Number of Estimates	2	2	3	3
Low Estimate	1.36	1.42	5.49	6.47
High Estimate	1.37	1.45	5.64	NA
Year Ago EPS	1.01	1.19	4.44	5.57
EPS Growth	35.15%	20.59%	25.45%	25.37%

More JAZZ Estimates

Average Earnings Estimates for JAZZ

EPS Growth for JAZZ

Industry Analysis

Name	Symbol	Previous Close
JAZZ PHARMACEUT	JAZZ	60.00
SALIX PHARM-LTD	SLXP	59.33
SANTARUS INC	SNTS	22.30
USANA HLTH SCI	USNA	67.95
BIOCRYST PHARMA	BCRX	1.70
CATALYST PHARMA	CPRX	0.91
CELL THERAPEUT	CTIC	1.32
CUBIST PHARM	CBST	55.46
ELAN CP PLC ADR	ELN	12.07
INFINITY PHARMA	INFI	25.13

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Additional Patent for Acorda's Ampyra

May 22, 2013

Generic Launches at Mylan Continue

May 22, 2013

AbbVie Extends Galapagos Deal

May 22, 2013

Elan Provides Strategic Update

May 21, 2013

FDA Accepts Actavis NDA

May 20, 2013

Good News for Novartis' Ilaris

May 15, 2013

Nektar Posts Wider Loss, Maintains View

May 15, 2013

Merck KGaA Posts Higher Y/Y Earnings

May 15, 2013

More JAZZ Zacks Commentary

Financials

EPS TTM	4.83
Sales	586
Net Income	304
Price/Earnings	12.42
Price/Book	3.00
Price/Cash Flow	10.17
Price/Sales	5.08

More JAZZ Financials

News

Buyers Accumulating Shares of Jazz Pharmaceuticals on 2.1x Above-Average Volume (JAZZ) - Financial News Network Online - Unusual Volume

May 22, 2013

Jazz Pharmaceuticals (JAZZ) Trading Near $61.80 Resistance Level - Freshbrewedmedia

May 22, 2013

Jazz Pharmaceuticals Makes a Move: Up 3.5% - Financial News Network Online - Market Movers

May 22, 2013

Relatively Good Performance Detected in Shares of Warner Chilcott in the Pharmaceuticals Industry (WCRX, MRK, JAZZ, SNY, VPHM) - Financial News Network Online - News Corner

May 22, 2013

Shares of Jazz Pharmaceuticals Rise to a New 52-Week High - Financial News Netwfork Online - 52-Week High-Lows

May 22, 2013

Jazz Pharmaceuticals Earnings Review: 13 Days after Announcement Shares Down 1.9% (JAZZ) - Comtex Smartrend(R)

May 20, 2013

Jazz Pharmaceuticals reports higher Q1 net income, provides outlook for 2013 - Datamonitor

May 20, 2013

Jazz Pharmaceuticals Earnings In Retrospect: Down 1.9% in the Last 11 Days (JAZZ) - Financial News Network Online - Earnings Lookback

May 18, 2013

See All News Stories on JAZZ

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	10
Average Target Price	74.30
Industry Rank by ABR	108 out of 265
Rank in Industry	1 out of 93

More JAZZ Broker Recommendations

Day Low - High	60.30 - 64.45
52wk Low - High	40.38 - 64.45
Previous Close	60.00
Avg. Volume	889,442
Industry	MED-DRUGS
Market Cap	3.48 B
Div - Yield	0.00 - 0.00
Beta	2.07
PE (Forward)	10.77
Current Year Est.	5.57
Quarterly Earnings ESP	0.00%

PE (Forward)	10.77
PEG Ratio	0.49
Current Year Est.	5.57
Current Quarter Estimate	1.37
Most Accurate Estimate	1.37
Earnings ESP	0.00%
Next Earnings Report Date	08-06-2013
EPS Last Year	4.83
Expected Earnings Growth	22.13%

Username: Password:

Remember me [?]

Jazz Pharmaceuticals Plc Ireland: (NASD: JAZZ)

$61.34

1.34 (2.23%)

Volume 2,042,343

May 22 03:24 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations